GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyclerion Therapeutics Inc (NAS:CYCN) » Definitions » 12-1 Month Momentum %

CYCN (Cyclerion Therapeutics) 12-1 Month Momentum % : -36.84% (As of Dec. 13, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Cyclerion Therapeutics 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-12-13), Cyclerion Therapeutics's 12-1 Month Momentum % is -36.84%.

The industry rank for Cyclerion Therapeutics's 12-1 Month Momentum % or its related term are showing as below:

CYCN's 12-1 Month Momentum % is ranked worse than
62.42% of 1445 companies
in the Biotechnology industry
Industry Median: -13.2 vs CYCN: -36.84

Competitive Comparison of Cyclerion Therapeutics's 12-1 Month Momentum %

For the Biotechnology subindustry, Cyclerion Therapeutics's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cyclerion Therapeutics's 12-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cyclerion Therapeutics's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Cyclerion Therapeutics's 12-1 Month Momentum % falls into.



Cyclerion Therapeutics  (NAS:CYCN) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cyclerion Therapeutics  (NAS:CYCN) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Cyclerion Therapeutics 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Cyclerion Therapeutics's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cyclerion Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
245 First Street, 18th Floor, Cambridge, MA, USA, 02142
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.
Executives
Slate Path Capital Lp 10 percent owner 717 5TH AVENUE, 16TH FL., NEW YORK NY 10022
Terrance Mcguire director C/O POLARIS VENTURE PARTNERS LP, 1000 WINTER STREET, SUITE 3350, WALTHAM MA 02154
Steven Hyman director C/O VOYAGER THERAPEUTICS, INC., 75 SIDNEY STREET, CAMBRIDGE MA 02139
Andreas Busch officer: Chief Scientific Officer C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
George H Conrades director 500 TECHNOLOGY SQUARE, FIFTH FLOOR, CAMBRIDGE MA 02139
Stephanie Lovell director C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Ole Isacson director CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Kevin Churchwell director C/O CYCLERION THERAPEUTICS, CAMBRIDGE MA 02142
Michael Mendelsohn director C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Peter M Hecht director, officer: Chief Executive Officer C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Errol B Desouza director 215 COLLEGE ROAD, PARAMUS NJ 07652
Anjeza Gjino officer: Chief Financial Officer C/O CYCLERION THERAPEUTICS, INC., 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE MA 02142
Christopher I Wright officer: Chief Medical Officer C/O CYCLERION THERAPEUTICS, INC., 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE MA 02142
Cheryl Gault officer: Chief Operating Officer CYCLERION THERAPEUTICS, INC., 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE MA 02142
Mark G Currie officer: President and CSO C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142